University of Pittsburgh.
Blood. 2020 May 28;135(22):1925-1926. doi: 10.1182/blood.2020006442.
In this issue of , DeBaun proposes a forward-thinking evidence-based strategy to limit the impact of the SARS-CoV-2 coronavirus disease (COVID-19) pandemic on children with sickle cell anemia (SCA) at high risk for stroke. DeBaun argues that rapid initiation of low- and fixed-dose (10 mg/kg per day) hydroxyurea treatment while the children are receiving prophylactic chronic transfusions, and before blood supply is disrupted, ensures that when blood shortages do occur, the clinical benefit of hydroxyurea will be more quickly established, and the children will be better protected.
本期《柳叶刀》杂志中，DeBaun 提出了一项具有前瞻性和循证医学的策略，旨在限制 SARS-CoV-2 冠状病毒病（COVID-19）大流行对镰状细胞贫血（SCA）高危儿童卒中的影响。DeBaun 认为，在儿童接受预防性慢性输血期间，且在血液供应中断之前，快速启动低剂量和固定剂量（每天 10mg/kg）羟基脲治疗，可以确保在确实出现血液短缺时，更快地建立羟基脲的临床获益，从而更好地保护儿童。
